Zanete Zvirbule

Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast Cancer

Angelo Di Leo, Henry Gómez, Zeba Aziz et al. · Journal of Clinical Oncology · 2008 · 421 citations · Full text

Medicine, Oncology, Pharmacology +17

A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study

Ö. Türeci, Uğur Şahin, Henning Schulze‐Bergkamen et al. · Annals of Oncology · 2019 · 244 citations · Full text

Medicine, Oncology, Pharmacology +17

Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage–SCLC: Results From the Phase 3 MERU Study

Melissa L. Johnson, Zanete Zvirbule, Åslaug Helland et al. · Journal of Thoracic Oncology · 2021 · 156 citations · Full text

Medicine, Oncology, Pharmacotherapy +8

A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis

Adam Brufsky, S.B. Kim, Zanete Zvirbule et al. · Annals of Oncology · 2021 · 88 citations · Full text

Medicine, Oncology, Pharmacology +17

Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial

István Láng, Thomas Brodowicz, Larisa Ryvo et al. · The Lancet Oncology · 2013 · 85 citations

Medicine, Oncology, Pharmacology +15